This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Glauser, T. A. Articles by Pellock, J. M. Search for Related Content PubMed PubMed Citation Articles by Glauser, T. A. Articles by Pellock, J. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Epilepsy Social Bookmarking                         What's this?

Tropical Review: Zonisamide in Pediatric Epilepsy: Review of the Japanese Experience

Department of Neurology Children's Comprehensive Epilepsy Program, Children's Hospital Medical Center, Cincinnati, OH

John M. Pellock, MD

Division of Child Neurology, Comprehensive Epilepsy Institute, Medical College of Virginia/Virginia Commonwealth University Richmond, VA

Zonisamide is a novel anticonvulsant that is structurally and mechanistically unique, compared with other antiepilepsy drugs. Available in Japan and South Korea since 1989, it was approved in the United States in the year 2000 as adjunctive therapy for partial seizures in adults. There has been extensive clinical trial and clinical practice experience with zonisamide therapy in Japanese children. Open-label data from pediatric clinical trials conducted in Japan suggest that zonisamide is well tolerated and effective against partial- and generalized-onset seizures in children. Despite this wealth of open-label data, no formal pharmacokinetic studies and only one well-controlled trial of zonisamide's efficacy and safety in Japanese children have been completed to date. No controlled clinical trials of zonisamide in children have been completed in the United States or Europe. Additional controlled trials in children with partial- or generalized-onset seizures, infantile spasms, and Lennox-Gastaut syndrome are warranted to further delineate zonisamide's broad spectrum of efficacy and tolerability in children. (J Child Neurol 2002;17:87-96).

Journal of Child Neurology, Vol. 17, No. 2, 87-96 (2002)
DOI: 10.1177/088307380201700201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. E. Mandelbaum, M. Bunch, S. L. Kugler, A. Venkatasubramanian, and J. B. Wollack Broad-Spectrum Efficacy of Zonisamide at 12 Months in Children With Intractable Epilepsy J Child Neurol, July 1, 2005; 20(7): 594 - 597. [Abstract] [PDF]

				H. L. Kim, J. Aldridge, and J. M. Rho Clinical Experience With Zonisamide Monotherapy and Adjunctive Therapy in Children With Epilepsy at a Tertiary Care Referral Center J Child Neurol, March 1, 2005; 20(3): 212 - 219. [Abstract] [PDF]

				T. A. Glauser Behavioral and Psychiatric Adverse Events Associated With Antiepileptic Drugs Commonly Used in Pediatric Patients J Child Neurol, August 1, 2004; 19(1_suppl): S25 - S38. [Abstract] [PDF]

				W. D. Shields Management of Epilepsy in Mentally Retarded Children Using the Newer Antiepileptic Drugs, Vagus Nerve Stimulation, and Surgery J Child Neurol, August 1, 2004; 19(1_suppl): S58 - S64. [Abstract] [PDF]

				T. A. Glauser Behavioral and Psychiatric Adverse Events Associated With Antiepileptic Drugs Commonly Used in Pediatric Patients J Child Neurol, January 1, 2004; 19(1_suppl): S25 - S38. [Abstract] [PDF]

				W. D. Shields Management of Epilepsy in Mentally Retarded Children Using the Newer Antiepileptic Drugs, Vagus Nerve Stimulation, and Surgery J Child Neurol, January 1, 2004; 19(1_suppl): S58 - S64. [Abstract] [PDF]